Indaptus Sells Shares at 81% Below Market to Stay Alive — Can $12 Million Buy Enough Time for a Clinical-Stage Biotech With No Revenue?

Shares of Indaptus Therapeutics shifted sharply this week as the clinical-stage cancer immunotherapy company announced a $12 million Regulation S private placement on July 1 — issuing 20 million new shares at just $0.60 apiece to non-U.S. investors. The stock dropped to $2.94 on the news but bounced 8.5% to $3.19 today as traders began to digest the dilution. For a company that was nearly out of cash earlier this year, the deal keeps the lights on — but at a brutal cost to existing shareholders.

• Sixty Cents on a Three-Dollar Stock Signals Desperation, Not Strength. At $0.60 per share, the placement is priced at roughly an 81% discount to yesterday's close. Indaptus's proxy filing for its July 28 annual meeting already sought shareholder approval to authorize private placements of up to $300 million at prices between $0.60 and $1.00 per share, potentially exceeding 20% of outstanding stock. That tells you management anticipated — and investors should expect — heavy dilution ahead. The 20 million new shares would expand the current 113.2 million shares outstanding by roughly 18%.

• The Company Was Running on Fumes. As of March 31, 2026, Indaptus held just $2.18 million in total assets against an accumulated deficit of $83.8 million.

The company previously warned that its cash would only support operations into Q1 2026. Without this raise, the runway was essentially zero. The $12 million buys perhaps two to three more quarters of operations — not comfort, just survival.

• The Clinical Story Is Still Early and Unproven. The company's lead drug candidate, an immunotherapy for advanced solid tumors, showed one partial tumor response in a single patient that was not sustained, and in early combination dosing of seven patients, only one showed stable disease while two saw their cancer worsen. That is thin data on which to bet a company's future.

• A Much Bigger Dilution Wave Could Be Coming. Major shareholder David Lazar purchased preferred stock convertible into 111 million common shares — nearly doubling the share count once converted. Combined with the $300 million placement authorization and this new deal, existing shareholders face a wall of potential dilution that could dwarf today's raise. The bounce looks like short-covering speculation, not a fundamental reassessment. Investors should treat INDP as a high-risk financing story first and a biotech play second.